Neurol. praxi. 2021;22(4):320-324 | DOI: 10.36290/neu.2021.047
Siponimod: the first drug in secondary progressive multiple sclerosis in clinical practice
- Neurologická klinika, Fakultní nemocnice Plzeň a Lékařská fakulta v Plzni, Univerzita Karlova
Siponimod is the first disease-modifying drug in the treatment of secondary progressive multiple sclerosis (SPRS). Its efficacy was demonstrated in the EXPAND trial. It is an oral selective sphingosine 1-phosphate receptor modulator, specifically of the 1 and 5 subtypes (S1P1, S1P5). Siponimod binds to the S1P1 receptors on lymphocytes, preventing their egress from lymph nodes, thus inhibiting their recirculation to the central nervous system (CNS). By crossing the blood-brain barrier, it affects the inflammatory and neurodegenerative processes occurring in the CNS during SPRS. A case report is used to show what treatment options for SPRS have been available so far and what siponimod can offer us and our patients.
Keywords: siponimod, secondary progressive multiple sclerosis, Expanded Disability Status Scale.
Received: June 18, 2021; Revised: June 18, 2021; Accepted: July 10, 2021; Published: September 1, 2021 Show citation
LMm_References
- Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360(9350): 2018-2025.
Go to original source... 
Go to PubMed... - Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983; 308(4): 173-180. Go to original source... Go to PubMed...
- Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018; 17(5): 405-415. Go to original source... Go to PubMed...
- Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018;391(10127):1263-1273. Go to original source... Go to PubMed...
- Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000; 54(5): 1145-1155. Go to original source... Go to PubMed...
- SÚKL [online]. 2020-06-30 [cit. 2021-04-28]. Dostupný na www: